Summary of the EQA material; genotypes and estimated tumour burden
| EQA run | Case number | Validated EGFR molecular result | Estimated tumour burden % |
|---|---|---|---|
| 2010 | 2010-1 | Deletion in exon 19 | Approximately 60–70 |
| 2010-2 | No mutations detected within exons 18–21 of the EGFR gene | Approximately 40–50 | |
| 2010-3 | c.2582A >T, p.(Leu861Gln) detected | Approximately 40–50 | |
| 2011 run 1 | 2011-1 | No mutations detected within exons 18–21 of the EGFR gene | Approximately 50–60 |
| 2011-2 | Deletion in exon 19 | Approximately 70 | |
| 2011-3 | c.2573T >G, p.(Leu858Arg) detected | Approximately 40–50 | |
| 2011 run 2 | 2011-4 | No mutations detected within exons 18–21 of the EGFR gene | Approximately 80 |
| 2011-5 | c.2573T >G, p.(Leu858Arg) detected | Approximately 30–40 | |
| 2011-6 | c.2156G >C, p.(Gly719Ala) detected | Approximately 50 |
Mutation nomenclature is according to GenBank accession number NM_005228.3 (with numbering starting at the A of the ATG initiation codon according to Human Genome Variation Society guidelines (http://www.hgvs.org.uk)).
EGFR, epidermal growth factor receptor; EQA, external quality assessment.